3 citations
,
May 2022 in “Clinical and experimental dermatology” Drugs targeting EMT molecules show promise for treating lichen planopilaris.
5 citations
,
June 2019 in “British Journal of Dermatology” Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
November 2024 in “Dermatology Online Journal” Dupilumab may help treat alopecia areata, but more research is needed.
1 citations
,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
1 citations
,
October 2024 in “QJM” IL-12/23 inhibitors are more effective and have fewer common side effects than anti-TNF alpha for treating psoriasis.
The treatment was ineffective in humans.
15 citations
,
November 2022 in “Cell Death and Disease” CEP135 may predict cancer outcomes, and targeting PLK1 could help treat certain sarcomas.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
December 2025 in “Journal of Human Immunity” JAK inhibitors may help improve symptoms in adults with APECED.
1 citations
,
November 2022 in “Journal of Investigative Dermatology” ALRN-6924 may prevent hair loss caused by chemotherapy.
52 citations
,
December 2014 in “Journal of Dermatological Science” Apremilast may help treat hair loss in alopecia areata.
Alopecia universalis from alemtuzumab in multiple sclerosis can be reversed with specific treatments.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” A patient with a new PLEC gene mutation showed symptoms of both muscular dystrophy and myasthenia gravis, which improved with steroid treatment.
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
November 2025 in “Journal of Investigative Dermatology”
April 2017 in “Journal of Investigative Dermatology” SM04755 may be an effective topical treatment for psoriasis.
3 citations
,
December 2021 in “Dermatology reports” Dupilumab can improve both atopic dermatitis and alopecia universalis.
January 2008 in “Projeto: revista mensal de arquitetura” Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.
December 2013 in “Nursing2023” The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
2 citations
,
October 2022 in “Current Allergy and Asthma Reports” Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology”
April 2023 in “Journal of Investigative Dermatology” Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.
Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.
1 citations
,
June 2018 in “Dermatologic Surgery”
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
August 2024 in “JAAD Case Reports” Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.
2 citations
,
January 2024 in “SAGE Open Medical Case Reports” Dupilumab can cause lupus-like symptoms, so patients need careful monitoring.
11 citations
,
September 2024 in “American Journal of Clinical Dermatology” Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.
August 2024 in “Indian Journal of Dermatology Venereology and Leprology” October 2017 in “Journal of Investigative Dermatology” Pemphigus vulgaris involves specific immune cells and B cells that produce antibodies causing skin blisters.